Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Antinociceptive activity of botulinum toxin type A (CROSBI ID 510888)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija

Laković, Zdravko ; Bach-Rojecky, Lidija ; Relja, Maja Antinociceptive activity of botulinum toxin type A // Parkinsonism & related disorders. 2005. str. 105-105

Podaci o odgovornosti

Laković, Zdravko ; Bach-Rojecky, Lidija ; Relja, Maja

engleski

Antinociceptive activity of botulinum toxin type A

Objective: Over the last 20 years botulinum toxin type A (BTX-A) has beeen used for treating a varity of disorders characgterized by increased muscle contraction and recently few clinical observations on several patients indicated that it might be useful in neuropathic pain. Here we owerview the efficacy of BTX-a in different models of pain in rat, from published studies and some new studies from our laboratory. Methods: All experiments were performed in rats. After dose-response and time-course experiments performed with BTX-A using formalin to provoke acute pain associated with inflammation the effectiveness of BTX-A on pain was tested. Results: 1. Pre-treatment with BTX-A 5 U/kg reduced enhances sensitvity to stimuli provoked with peripheral carrageenan or capsaicin injection. This reduction was significant then BTX-A was aplied 6 days before the induction of pain and wa ineffective when applied 24 h before the challenge. 2.A peripheral application of botulinum toxin type A (7 U/kg) reduced hypersensitivity in rats with the partial sciatic nerve transection. 3. BTX-A was effective in pain induced injection of low pH Saline Conclusions: The results obtained in our laboratory clearly demonstrate antinociceptive activity of small doses of BTX-A in experimental animals. Since single applicaton of BTX-A in rat produces antinociceptive effect lasting 12-15 days or more the potential significance for pain pharmacology is more than clear. However, (a) five days delay in the onset of antinociceptive activity of peripherally applied BTX-A, (b) its effectivness in different models of experimental pain, (c) its inefectiveness in reducing carrageenan iduced paw-edema indicate that the nociceptive effect of BTX-A might be more complex than suggested inhibition of transmitter release in the periphery.

Botulinum toxin type A; pain

Peter Franz Riederer, Susanne W. Burns, Manfred Gerlach (ur.) ; DOI: 10.1016/S1353-8020(05)80088-4

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

105-105.

2005.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

Parkinsonism & related disorders

1353-8020

Podaci o skupu

International Congress on Parkinson's Disease and Related Disorders (16 ; 2005)

poster

01.01.2005-01.01.2005

Povezanost rada

Temeljne medicinske znanosti

Indeksiranost